Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells

Weiyan Zheng, Min Guan, Lijun Zhu, Zhen Cai, Vincent Chung, He Huang, Yun Yen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in many malignant cancer patients, including those with lymphoma. This study investigated whether the therapeutic effect of bortezomib in lymphoma is associated with FGFR3-expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U937 cells and compared to U937 cells overexpressing FGFR3 wild-type, or Y373C or K650E mutant FGFR3. Results: Results from this study suggested the expression of FGFR3 protein is associated with the therapeutic effect of bortezomib. It was observed that bortezomib-induced apoptotic death is correlated with FGFR3 expression. U937 cells overexpression of wild-type FGFR3 demonstrated resistance to bortezomib treatment. U937 cells expressing Y373C mutated FGFR3 showed an almost equal resistance to bortezomib as U937 cells expressing wild-type FGFR3. U937 cells expressing mutated K650E FGFR3 showed more sensitivity to bortezomib than did the parental U937 cells. Furthermore, increased expression of Mcl-1 and decreased expression of NF-κB p65 suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through Bcl-2 and NF-κB signaling. Conclusion: Data from this study indicate that mutation status and the expression level of FGFR3 may be associated with bortezomib-related treatment resistance in lymphoma.

Original languageEnglish
Pages (from-to)1921-1930
Number of pages10
JournalAnticancer Research
Volume30
Issue number6
Publication statusPublished - Jun 1 2010
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Therapeutic Uses
Lymphoma
U937 Cells
Mutation
Bortezomib

Keywords

  • Bortezomib
  • Fibroblast growth factor receptor 3 (FGFR3)
  • Lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zheng, W., Guan, M., Zhu, L., Cai, Z., Chung, V., Huang, H., & Yen, Y. (2010). Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Research, 30(6), 1921-1930.

Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. / Zheng, Weiyan; Guan, Min; Zhu, Lijun; Cai, Zhen; Chung, Vincent; Huang, He; Yen, Yun.

In: Anticancer Research, Vol. 30, No. 6, 01.06.2010, p. 1921-1930.

Research output: Contribution to journalArticle

Zheng, W, Guan, M, Zhu, L, Cai, Z, Chung, V, Huang, H & Yen, Y 2010, 'Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells', Anticancer Research, vol. 30, no. 6, pp. 1921-1930.
Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H et al. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Research. 2010 Jun 1;30(6):1921-1930.
Zheng, Weiyan ; Guan, Min ; Zhu, Lijun ; Cai, Zhen ; Chung, Vincent ; Huang, He ; Yen, Yun. / Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. In: Anticancer Research. 2010 ; Vol. 30, No. 6. pp. 1921-1930.
@article{726488142d1a49838b8d56d7cc889ba2,
title = "Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells",
abstract = "Objective: Ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in many malignant cancer patients, including those with lymphoma. This study investigated whether the therapeutic effect of bortezomib in lymphoma is associated with FGFR3-expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U937 cells and compared to U937 cells overexpressing FGFR3 wild-type, or Y373C or K650E mutant FGFR3. Results: Results from this study suggested the expression of FGFR3 protein is associated with the therapeutic effect of bortezomib. It was observed that bortezomib-induced apoptotic death is correlated with FGFR3 expression. U937 cells overexpression of wild-type FGFR3 demonstrated resistance to bortezomib treatment. U937 cells expressing Y373C mutated FGFR3 showed an almost equal resistance to bortezomib as U937 cells expressing wild-type FGFR3. U937 cells expressing mutated K650E FGFR3 showed more sensitivity to bortezomib than did the parental U937 cells. Furthermore, increased expression of Mcl-1 and decreased expression of NF-κB p65 suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through Bcl-2 and NF-κB signaling. Conclusion: Data from this study indicate that mutation status and the expression level of FGFR3 may be associated with bortezomib-related treatment resistance in lymphoma.",
keywords = "Bortezomib, Fibroblast growth factor receptor 3 (FGFR3), Lymphoma",
author = "Weiyan Zheng and Min Guan and Lijun Zhu and Zhen Cai and Vincent Chung and He Huang and Yun Yen",
year = "2010",
month = "6",
day = "1",
language = "English",
volume = "30",
pages = "1921--1930",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells

AU - Zheng, Weiyan

AU - Guan, Min

AU - Zhu, Lijun

AU - Cai, Zhen

AU - Chung, Vincent

AU - Huang, He

AU - Yen, Yun

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Objective: Ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in many malignant cancer patients, including those with lymphoma. This study investigated whether the therapeutic effect of bortezomib in lymphoma is associated with FGFR3-expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U937 cells and compared to U937 cells overexpressing FGFR3 wild-type, or Y373C or K650E mutant FGFR3. Results: Results from this study suggested the expression of FGFR3 protein is associated with the therapeutic effect of bortezomib. It was observed that bortezomib-induced apoptotic death is correlated with FGFR3 expression. U937 cells overexpression of wild-type FGFR3 demonstrated resistance to bortezomib treatment. U937 cells expressing Y373C mutated FGFR3 showed an almost equal resistance to bortezomib as U937 cells expressing wild-type FGFR3. U937 cells expressing mutated K650E FGFR3 showed more sensitivity to bortezomib than did the parental U937 cells. Furthermore, increased expression of Mcl-1 and decreased expression of NF-κB p65 suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through Bcl-2 and NF-κB signaling. Conclusion: Data from this study indicate that mutation status and the expression level of FGFR3 may be associated with bortezomib-related treatment resistance in lymphoma.

AB - Objective: Ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in many malignant cancer patients, including those with lymphoma. This study investigated whether the therapeutic effect of bortezomib in lymphoma is associated with FGFR3-expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U937 cells and compared to U937 cells overexpressing FGFR3 wild-type, or Y373C or K650E mutant FGFR3. Results: Results from this study suggested the expression of FGFR3 protein is associated with the therapeutic effect of bortezomib. It was observed that bortezomib-induced apoptotic death is correlated with FGFR3 expression. U937 cells overexpression of wild-type FGFR3 demonstrated resistance to bortezomib treatment. U937 cells expressing Y373C mutated FGFR3 showed an almost equal resistance to bortezomib as U937 cells expressing wild-type FGFR3. U937 cells expressing mutated K650E FGFR3 showed more sensitivity to bortezomib than did the parental U937 cells. Furthermore, increased expression of Mcl-1 and decreased expression of NF-κB p65 suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through Bcl-2 and NF-κB signaling. Conclusion: Data from this study indicate that mutation status and the expression level of FGFR3 may be associated with bortezomib-related treatment resistance in lymphoma.

KW - Bortezomib

KW - Fibroblast growth factor receptor 3 (FGFR3)

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=77955084287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955084287&partnerID=8YFLogxK

M3 - Article

C2 - 20651335

AN - SCOPUS:77955084287

VL - 30

SP - 1921

EP - 1930

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -